-
- Saigusa Daisuke
- Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University Tohoku Medical Megabank Organization, Tohoku University
この論文をさがす
説明
<p>The metabolome is a group of small molecules that reflect phenotypic changes; this set of molecules is a potential source of biomarkers to predict the risk of disease development and progression. Therefore, it is necessary to establish a comprehensive and precise method to analyze the metabolome in biological samples. Mass spectrometry (MS) is one of the most suitable technologies to detect those molecules for metabolic profiling. In particular, liquid chromatography (LC)-MS-based methodology has been applied to various disease models and clinical samples, and biomarker candidates have been identified in previous studies. However, it is necessary to clarify their functions by in vivo research, and their molecular mechanisms in cells and/or tissues should be considered before the markers are deemed clinically applicable. MS imaging (MSI) is a promising technology that can visualize molecules on tissue surfaces without labeling and thus can clarify the distribution of biomarker candidates on tissue to evaluate the results by means of LC-MS-based analysis. Here, we describe the outline of the protocols for biomarker discovery by LC-MS and explain the utilization of integrated analyses using LC-MS and MSI to evaluate the function of biomarker candidates.</p>
収録刊行物
-
- Medical Mass Spectrometry
-
Medical Mass Spectrometry 7 (1), 2-16, 2023-06-25
一般社団法人 日本医用マススペクトル学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390019058250207744
-
- NII書誌ID
- AA12788254
-
- ISSN
- 2432745X
- 24327441
-
- NDL書誌ID
- 032940024
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
-
- 抄録ライセンスフラグ
- 使用不可